MA53706A - Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne - Google Patents

Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne

Info

Publication number
MA53706A
MA53706A MA053706A MA53706A MA53706A MA 53706 A MA53706 A MA 53706A MA 053706 A MA053706 A MA 053706A MA 53706 A MA53706 A MA 53706A MA 53706 A MA53706 A MA 53706A
Authority
MA
Morocco
Prior art keywords
treatment
bacterial infection
indane derivatives
indane
derivatives
Prior art date
Application number
MA053706A
Other languages
English (en)
Inventor
Lilha Beyria
Toby Jonathan Blench
David Edward Clark
Andrew Peter Cridland
David Thomas Davies
Richard Leonard Elliott
Martin Everett
Simon Leiris
Thomas David Pallin
Nicolas Sprynski
Original Assignee
Antabio Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18290106.6A external-priority patent/EP3628666A1/fr
Application filed by Antabio Sas filed Critical Antabio Sas
Publication of MA53706A publication Critical patent/MA53706A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
MA053706A 2018-09-25 2019-07-25 Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne MA53706A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18290106.6A EP3628666A1 (fr) 2018-09-25 2018-09-25 Dérivés d'indane pour le traitement des infections bactériennes
EP18290104 2018-09-26
EP18197365 2018-09-27

Publications (1)

Publication Number Publication Date
MA53706A true MA53706A (fr) 2021-12-29

Family

ID=67439236

Family Applications (2)

Application Number Title Priority Date Filing Date
MA053706A MA53706A (fr) 2018-09-25 2019-07-25 Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne
MA053707A MA53707A (fr) 2018-09-25 2019-07-25 Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA053707A MA53707A (fr) 2018-09-25 2019-07-25 Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne

Country Status (14)

Country Link
US (2) US12286411B2 (fr)
EP (2) EP3856729A1 (fr)
JP (2) JP7429993B2 (fr)
KR (2) KR102833646B1 (fr)
CN (2) CN113166084B (fr)
AU (2) AU2019349438B2 (fr)
BR (2) BR112021005651A2 (fr)
CA (2) CA3113689A1 (fr)
CL (2) CL2021000729A1 (fr)
IL (2) IL281770B2 (fr)
MA (2) MA53706A (fr)
MX (2) MX2021003498A (fr)
SG (2) SG11202102791SA (fr)
WO (2) WO2020064174A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202102791SA (en) 2018-09-25 2021-04-29 Antabio Sas Indane derivatives for use in the treatment of bacterial infection
US20240016941A1 (en) * 2020-03-24 2024-01-18 Antabio Sas Combination therapy
WO2025235845A1 (fr) * 2024-05-09 2025-11-13 The Regents Of The University Of California Compositions antibiotiques et leurs méthodes d'utilisation

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU569719B2 (en) 1983-01-28 1988-02-18 Schering Corporation Phosphorous compounds as inhibitors of enkephalinases
US5457196A (en) * 1991-09-27 1995-10-10 Merrell Dow Pharmaceuticals Inc. 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
JP3126541B2 (ja) 1993-03-26 2001-01-22 千寿製薬株式会社 ベンゾチアゾール誘導体、その製法及びその用途
JPH0782259A (ja) * 1993-09-14 1995-03-28 Senju Pharmaceut Co Ltd スクシンアミド酸誘導体及びそれを含有する糖尿病合併症治療剤
DE4339198A1 (de) 1993-11-16 1995-05-18 Max Planck Gesellschaft Verwendung bestimmter aromatischer Derivate als Fungizide und/oder Antibiotika
US6514996B2 (en) 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
AU725735B2 (en) 1996-07-23 2000-10-19 Daiichi Pharmaceutical Co., Ltd. Absorption enhancer
JPH11130761A (ja) 1997-10-24 1999-05-18 Otsuka Pharmaceut Co Ltd ベンゾチアゾール誘導体
AR036237A1 (es) 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
UA79755C2 (en) 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
WO2003094889A1 (fr) 2002-05-13 2003-11-20 Daiichi Pharmaceutical Co., Ltd. Produit de lyophilisation
PA8597401A1 (es) 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
WO2005016249A2 (fr) 2003-07-11 2005-02-24 Pharmacia Corporation Compositions constituees d'un inhibiteur chromene ou acide phenylacetique selectif de la cyclooxygenase-2 et d'un inhibiteur de ace pour traiter les lesions du systeme nerveux central
US7659300B2 (en) 2004-09-08 2010-02-09 Merck Sharp & Dohme Corp. Monocyclic anilide spirolactam CGRP receptor antagonists
FR2883876B1 (fr) 2005-03-30 2007-05-04 Servier Lab Derives d'indanyl-piperazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR20080014024A (ko) 2005-05-11 2008-02-13 아보트 러보러터리즈 바닐로이드 수용체 아형 １(ｖｒ１)의 길항제 및 이의 용도
US7674507B2 (en) 2005-05-25 2010-03-09 Merck Patent Gmbh Pyran-dioxane derivatives, and the use thereof in liquid-crystalline media
WO2007031860A1 (fr) 2005-09-15 2007-03-22 Pfizer Japan Inc. Benzimidazoles substitués par un indane et leur emploi en tant qu’inhibiteurs de la pompe à acide
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2007099423A1 (fr) 2006-03-02 2007-09-07 Pfizer Products Inc. Dérivés de 1-pyrrolidine indane en tant qu'antagonistes du récepteur d'histamine 3
WO2008036967A2 (fr) 2006-09-22 2008-03-27 Reddy Us Therapeutics, Inc. Nouveaux composes heterocycliques utilises en tant qu'activateurs de la synthase d'acide lipoique
EP2155711A1 (fr) 2007-06-05 2010-02-24 Sanofi-Aventis Acides benzoylamino-indan-2-carboxyliques substitués et composés apparentés
EP2141164A1 (fr) 2008-07-01 2010-01-06 Mutabilis Nouveaux dérivés 1,2,4-triazine et leurs applications biologiques
US8877815B2 (en) * 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
JP2014510065A (ja) 2011-03-02 2014-04-24 バイオノミックス リミテッド 治療薬としての新規な小分子
CN104837351A (zh) * 2012-11-30 2015-08-12 拜耳作物科学股份公司 二元杀真菌或杀虫混合物
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
GB201704476D0 (en) * 2017-03-21 2017-05-03 Antabio Sas Chemical compounds
CN117263942A (zh) 2018-03-21 2023-12-22 传达治疗有限公司 Shp2磷酸酶抑制剂及其使用方法
SG11202102791SA (en) 2018-09-25 2021-04-29 Antabio Sas Indane derivatives for use in the treatment of bacterial infection
JP7528065B2 (ja) 2018-09-26 2024-08-05 アルカヘスト，インコーポレイテッド Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物
US12435044B2 (en) 2018-09-27 2025-10-07 Fmc Corporation Pyridazinone herbicides and pyridazinone intermediates used to prepare a herbicide

Also Published As

Publication number Publication date
JP7429993B2 (ja) 2024-02-09
MA53707A (fr) 2021-12-29
BR112021005532A2 (pt) 2021-06-29
IL281780B1 (en) 2025-11-01
AU2019349438B2 (en) 2024-12-12
EP3856729A1 (fr) 2021-08-04
IL281770B2 (en) 2025-03-01
AU2019349438A1 (en) 2021-04-15
KR20210087448A (ko) 2021-07-12
KR20210087025A (ko) 2021-07-09
IL281780A (en) 2021-05-31
US20210347748A1 (en) 2021-11-11
CN113166084B (zh) 2024-06-04
IL281770B1 (en) 2024-11-01
WO2020064174A1 (fr) 2020-04-02
SG11202102790PA (en) 2021-04-29
BR112021005651A2 (pt) 2021-06-22
JP7429992B2 (ja) 2024-02-09
CN113166085B (zh) 2024-04-09
WO2020064173A1 (fr) 2020-04-02
CL2021000731A1 (es) 2021-11-05
KR102833669B1 (ko) 2025-07-11
MX2021003498A (es) 2021-09-10
CN113166084A (zh) 2021-07-23
IL281780B2 (en) 2026-03-01
EP3856730A1 (fr) 2021-08-04
CN113166085A (zh) 2021-07-23
US20220112169A1 (en) 2022-04-14
JP2022502485A (ja) 2022-01-11
AU2019351551B2 (en) 2024-12-12
CA3113697A1 (fr) 2020-04-02
US12286411B2 (en) 2025-04-29
IL281770A (en) 2021-05-31
SG11202102791SA (en) 2021-04-29
CL2021000729A1 (es) 2021-11-05
CA3113689A1 (fr) 2020-04-02
JP2022502486A (ja) 2022-01-11
US12247013B2 (en) 2025-03-11
KR102833646B1 (ko) 2025-07-11
AU2019351551A1 (en) 2021-04-15
MX2021003485A (es) 2021-09-10

Similar Documents

Publication Publication Date Title
MA54229A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
MA49760A (fr) Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique
EP3405183A4 (fr) Dérivés d'adamatane pour le traitement d'une infection à filovirus
MA44020B1 (fr) Composés antitumoraux
MA54515A (fr) Dérivés de quinoléine destinés à être utilisés dans le traitement de maladies inflammatoires
MA50800A (fr) Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
MA50905A (fr) Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques
EP3442519A4 (fr) Compositions de disulfure de sélénium destinées à être utilisées dans le traitement du dysfonctionnement de la glande de meibomius
EP3572050A4 (fr) Agent de traitement d'excréments destiné à être utilisé dans des colostomies
EP3374350A4 (fr) Composés à base d'hydroxypyridinone et d'hydroxypyrimidinone pour le traitement d'infections bactériennes
MA55821A (fr) Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression
MA40221A (fr) Dérivés d'isoindoline à utiliser dans le traitement d'une infection virale
EP3890749A4 (fr) Inhibiteurs de cdk9 et leurs polymorphes destinés à être utilisés en tant qu'agents pour le traitement du cancer
MA53562A (fr) Polythérapie destinée au traitement d'une maladie hépatique
EP3655404A4 (fr) Composés et leur utilisation pour le traitement d'infections microbiennes
EP3641746A4 (fr) Méthodes et compositions pour le traitement d'une infection microbienne
EP4069700A4 (fr) Macrocycles destinés à être utilisés dans le traitement d'une maladie
MA53707A (fr) Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne
MA52137A (fr) Méthodes de traitement de l'amylose ttr à l'aide d'ag10
EP3768274A4 (fr) Composition destinée à être utilisée dans le traitement d'états provoqués par une déficience en calcium
EP3645120A4 (fr) Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
MA47111A (fr) Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
EP3592349A4 (fr) Administration de composés antibiotiques pour le traitement d'infections streptococciques, pour le traitement du psoriasis
EP3648769A4 (fr) N-acyl amides dérivés du microbiote humain pour le traitement d'une maladie humaine
EP3654961A4 (fr) Méthodes et compositions pour le traitement de la douleur à l'aide de la capsaïcine